GlassScriptPhysician profile
Michael J Hodkin
NPI 1003899436
$4,380.19
in general payments reported to CMS, 2019-2025
24 companies · $932 in 2025
The $932 reported for 2025 was more than what 75% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $427 · 2020: $220 · 2021: $837 · 2022: $108 · 2023: $512 · 2024: $1,344 · 2025: $932.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,761 · Honoraria: $27.78.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,760.52 |
| Honoraria | $27.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $745.97 | 2019-2025 | Centurion, Rocklatan, Clareon |
| Bausch & Lomb Americas INC. | $626.86 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Sun Pharmaceutical Industries INC. | $357.61 | 2019-2025 | Cequa |
| Mallinckrodt Hospital Products INC. | $349.81 | 2021-2025 | Acthar |
| Glaukos Corporation | $340.63 | 2024-2025 | Idose, Idosetr, Istent Infinite Trabecular Micro Bypass System |
| Rxsight INC | $320.24 | 2024-2025 | Rxsight Injector Handpiece, Rxsight Injector Cartridge, Light Adjustable Lens (Lal) |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $274.36 | 2019-2021 | |
| Dompe US, INC. | $209.77 | 2024-2025 | Oxervate |
| Aerie Pharmaceuticals, INC. | $207.27 | 2020-2021 | |
| Allergan, INC. | $186.08 | 2019-2021 | |
| Abbvie INC. | $125.09 | 2025 | |
| Kala Pharmaceuticals, INC. | $106.58 | 2021 | |
| New World Medical,INC. | $80.80 | 2021-2024 | Clearpath, Streamline, Ahmed Glaucoma Valve |
| Tarsus Pharmaceuticals, INC. | $74.55 | 2024-2025 | Xdemvy |
| Novartis Pharmaceuticals Corporation | $74.36 | 2019-2020 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $67.45 | 2019-2025 | Baerveldt Glaucoma Implant (250) |
| Biotissue Holdings INC. | $50.82 | 2021-2024 | |
| Lensar, INC. | $39.19 | 2020-2024 | Lensar Laser System |
| Shire North American Group INC | $34.58 | 2019 | |
| Ocular Therapeutix, INC. | $31.62 | 2021-2024 | Dextenza |
| Sight Sciences, INC. | $27.23 | 2024 | Omni Surgical System |
| Amgen INC. | $17.73 | 2025 | Tepezza |
| Thea Pharma INC. | $16.04 | 2025 | Iyuzeh |
| Horizon Therapeutics Plc | $15.55 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Hodkin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.